Dr. Chiesa Fuxench discusses the role of topical ruxolitinib for patients with mild-to-moderate atopic dermatitis, including those who have not...
Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate...
Donna Lam Cahill, PA-C, outlines the psychosocial burdens of vitiligo, emphasizing that a patient’s disease burden does not always correlate...
Walter J. Liszewski, MD, an associate professor of dermatology at Northwestern University, discusses mechanisms of action to consider for treatment...
Joseph Fakhoury, MD: Special Considerations in Severe Alopecia Areata
Raj Chovatiya, MD, PhD, MSCI: Intravenous vs Subcutaneous GPP Therapy
James Del Rosso, DO: JCAD August 2026 Issue Highlights
Jeffrey Cohen, MD, MPH: Treating Psoriasis in High-Impact Sites
Jason Hawkes, MD, MS: The IL-36 Inflammatory Pathway and Generalized Pustular Psoriasis
